Comparison of DOTA and NODAGA as chelators for 64Cu-labeled immunoconjugates

To the best of our knowledge, this study represents the first comparison of 64Cu-labeled DOTA and NODAGA immunoconjugates in vivo. Our results show favorable in vivo performance for 64Cu-NODAGA-mAb7 which builds upon previous data on our hybrid mAb7 imaging agent by increasing the detection sensitivity for metastatic prostate tumors, as well as for other types of cancer that express EpCAM.